Treatment of human prostate cancer cells with dolastatin 10, a peptide isolated from a marine shell‐less mollusc

Turner, Timothy; Jackson, William H.; Pettit, George R.; Wells, Alan; Kraft, Andrew S.

doi:10.1002/(sici)1097-0045(19980215)34:3<175::aid-pros4>3.3.co;2-p

Cited by 10 publications

(14 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IC 50 values for 1F6 ADC-mediated proliferation inhibition ranged from 1 to 247 ng/mL for CD70-positive RCC lines. Similar IC 50 values were obtained in cytotoxicity assay using Caki-1, Caki-2, 786-O, A498, and CAL54 cells. At these ADC concentrations, the molar concentration of MMAF delivered by 1F6 ranged from 0.1 to 37 nmol/L (Table 2), considerably lower than the concentrations of free MMAF needed to achieve equivalent cell killing (Table 2).…”

Section: Cancer Researchsupporting

confidence: 80%

“…The IC 50 values of 1F6 ADC on proliferation inhibition and cytotoxicity were ( Fig. 2; Table 2) well below saturation levels for binding, ( Fig.…”

Section: Discussionmentioning

confidence: 86%

“…Auristatins are synthetic analogues of the natural product dolastatin 10, which interacts with the Vinca alkaloid-binding site on a-tubulin to prevent tubulin polymerization (48)(49)(50). ADCs consisting of auristatin E induce G 2 -M phase arrest in target cells preceding the onset of apoptosis (34,37).…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Lymphocyte Activation Antigen CD70 Expressed by Renal Cell Carcinoma Is a Potential Therapeutic Target for Anti-CD70 Antibody-Drug Conjugates

et al. 2006

View full text Add to dashboard Cite

Metastatic renal cell carcinoma (RCC) is an aggressive disease refractory to most existing therapeutic modalities. Identifying new markers for disease progression and drug targets for RCC will benefit this unmet medical need. We report a subset of clear cell and papillary cell RCC aberrantly expressing the lymphocyte activation marker CD70, a member of the tumor necrosis factor superfamily. Importantly, CD70 expression was found to be maintained at the metastatic sites of RCC. Anti-CD70 antibody-drug conjugates (ADC) consisting of auristatin phenylalanine phenylenediamine (AFP) or monomethyl auristatin phenylalanine (MMAF), two novel derivatives of the anti-tubulin agent auristatin, mediated potent antigendependent cytotoxicity in CD70-expressing RCC cells. Cytotoxic activity of these anti-CD70 ADCs was associated with their internalization and subcellular trafficking through the endosomal-lysosomal pathway, disruption of cellular microtubule network, and G 2 -M phase cell cycle arrest. The efficiency of drug delivery using anti-CD70 as vehicle was illustrated by the much enhanced cytotoxicity of antibodyconjugated MMAF compared with free MMAF. Hence, ADCs targeted to CD70 can selectively recognize RCC, internalize, and reach the appropriate subcellular compartment(s) for drug release and tumor cell killing. In vitro cytotoxicity of these ADCs was confirmed in xenograft models using RCC cell lines. Our findings provide evidence that CD70 is an attractive target for antibody-based therapeutics against metastatic RCC and suggest that anti-CD70 ADCs can provide a new treatment approach for advanced RCC patients who currently have no

show abstract

Section: Cancer Researchsupporting

confidence: 80%

“…The IC 50 values of 1F6 ADC on proliferation inhibition and cytotoxicity were ( Fig. 2; Table 2) well below saturation levels for binding, ( Fig.…”

Section: Discussionmentioning

confidence: 86%

See 1 more Smart Citation

Lymphocyte Activation Antigen CD70 Expressed by Renal Cell Carcinoma Is a Potential Therapeutic Target for Anti-CD70 Antibody-Drug Conjugates

et al. 2006

View full text Add to dashboard Cite

show abstract

“…Several studies have shown that peptides from different sources such as sea hare Turner et al, 1998;Madden et al, 2000;Vaishampayan et al, 2000;Woyke et al, 2001), fish sauce (Thang and Zhao, 2015;Bah et al, 2016), and cod (Xhindoli et al, 2016) were able to block proliferation of carcinogenic cells. However, it seems there is still a long way in order to make commercial use of these potentially potent anticancer peptides to treat different kinds of cancer.…”

Section: Cytomodulatory Effectmentioning

confidence: 99%

Peptides: Production, bioactivity, functionality, and applications

Hajfathalian

Ghelichi

Moreno

et al. 2017

Critical Reviews in Food Science and Nutrition

120

View full text Add to dashboard Cite

Production of peptides with various effects from proteins of different sources continues to receive academic attention. Researchers of different disciplines are putting increasing efforts to produce bioactive and functional peptides from different sources such as plants, animals, and food industry by-products. The aim of this review is to introduce production methods of hydrolysates and peptides and provide a comprehensive overview of their bioactivity in terms of their effects on immune, cardiovascular, nervous, and gastrointestinal systems. Moreover, functional and antioxidant properties of hydrolysates and isolated peptides are reviewed. Finally, industrial and commercial applications of bioactive peptides including their use in nutrition and production of pharmaceuticals and nutraceuticals are discussed.

show abstract

“…Previous studies with mitotic inhibitors from marine organisms are dominated by the compounds of low-molecularweight. Dolastatin 10, an anti-cancer peptide isolated from the sea hare, could block cells in G2/M phase by inhibiting tubulin polymerization (45)(46)(47)(48). Our results suggested that MML, likes Dolastatin 10, also induced cell arrest in G2/M phase and the effect might attribute to its inhibition effect on tubulin polymerization.…”

Section: Discussionmentioning

confidence: 64%

A novel anti-tumor protein extracted from Meretrix meretrix Linnaeus induces cell death by increasing cell permeability and inhibiting tubulin polymerization

Ning

Zhao²,

Zhang³

et al. 2009

Int J Oncol

View full text Add to dashboard Cite

Abstract. Discovery and development of new pharmaceuticals from marine organisms are attracting increasing interest. Several agents derived from marine organisms are under preclinical and clinical evaluation as potential anticancer drugs. We extracted and purified a novel anti-tumor protein from the coelomic fluid of Meretrix meretrix Linnaeus by ammonium sulphate fractionation, ion exchange and hydrophobic interaction chromatography. The molecular weight of the highly purified protein, designated MML, was 40 kDa as determined by SDS-PAGE analysis. MML exhibited significant cytotoxicity to several cancer cell types, including human hepatoma BEL-7402, human breast cancer MCF-7 and human colon cancer HCT116 cells. However, no inhibitory effect was found when treating murine normal fibroblasts NIH3T3 and benign human breast MCF-10A cells with MML. The cell death induced by MML was characterized by cell morphological changes. The induction of apoptosis of BEL-7402 cells by MML was weak by DNA ladder assay. The possible mechanisms of its anti-tumor effect might be the changes in cell membrane permeability and inhibition of tubulin polymerization. MML may be developed as a novel, highly selective and effective anti-cancer drug.

show abstract

Treatment of human prostate cancer cells with dolastatin 10, a peptide isolated from a marine shell‐less mollusc

Cited by 10 publications

References 0 publications

Lymphocyte Activation Antigen CD70 Expressed by Renal Cell Carcinoma Is a Potential Therapeutic Target for Anti-CD70 Antibody-Drug Conjugates

Lymphocyte Activation Antigen CD70 Expressed by Renal Cell Carcinoma Is a Potential Therapeutic Target for Anti-CD70 Antibody-Drug Conjugates

Peptides: Production, bioactivity, functionality, and applications

A novel anti-tumor protein extracted from Meretrix meretrix Linnaeus induces cell death by increasing cell permeability and inhibiting tubulin polymerization

Contact Info

Product

Resources

About